Ibrutinib Added to Standard Conditioning and As Consolidation Following Autologous Hematopoietic Stem Cell Transplantation (AutoHCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Results from the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201
      Google Scholar   
Citation:
Blood vol 41 (Supplement 1) 437
Meeting Instance:
ASH 2023
Year:
2023
Type:
Abstract
Sub type:
Oral
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
epub
Note:
Methodological:
No
Biospecimen:
Yes
SDC:
No
Parents:
None
Children:
4550  
Program:
OGC
Primary Committee:
Lymphoma
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U24CA196171; U10CA180820, UG1CA233234 (ECOG-ACRIN); U10CA180868 (NRG); U10CA180888 (SWOG);  
Corr. Author:
 
Authors:
                                   
Networks:
CA824, IL017, LAPS-IL036, LAPS-MN026, LAPS-MO011, LAPS-NC010, LAPS-NY016, LAPS-OH007, LAPS-WI013, NY018, OH027, PA121   
Study
Alliance-A051301
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
3
Keywords: